Stimulation of GALT and activation of mesenteric lymph node lymphocytes by a modified lysozyme in CBA mice with MCa mammary carcinoma.
Lysozyme (hen egg-white lysozyme) and its derivative mPEG-lyso (lysozyme coupled with polyoxyethyleneglycol) were tested in CBA mice bearing MCa mammary carcinoma for their effects on intestinal mucosal immunity (GALT) and mesenteric lymph node lymphocytes (MLNL), after oral administration. Following a cycle of administration of 100 mg/kg/day lysozyme or 350 mg/kg/day mPEG-lyso for 9 consecutive days, GALT was analyzed by using optical histology, and mesenteric lymph node lymphocytes were studied by cytofluorimetric analysis of CD3, CD4 and CD8 antigens, and of DNA and RNA content following in vitro culture with concanavalin A. Both lysozymes significantly increase the number of lymphatic nodules on gut epithelium as determined by histological analysis of sections of small bowel. mPEG-lyso, unlike native lysozyme, gives protection from the decline of the blastogenic activity of MLNL observed at early stages of tumor growth, as shown by the increased nucleic acid content of these cells. On the same cells, both lysozyme and mPEG-lyso also seem to prevent the decline of CD4+ cells observed during tumor growth in control animals. These data confirm the effects of lysozyme on GALT and show that the new lysozyme derivative mPEG-lyso has effects on host immunity greater than those of the native molecule.
Sava
G
G
Fondazione Callerio, Institutes of Biological Research, Trieste, Italy.
Bergamo
A
A
Capozzi
I
I
Clerici
K
K
Pacor
S
S
Gagliardi
R
R
Giacomello
E
E
Zacchigna
M
M
Di Luca
G
G
Boccu
E
E
D000818:Animals; D002277:Carcinoma / Q000378:metabolism / Q000473:pathology*; D004273:DNA, Neoplasm / Q000032:analysis / Q000096:biosynthesis; D004064:Digestive System / Q000187:drug effects / Q000473:pathology*; D005260:Female; D008198:Lymph Nodes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology*; D008643:Mesentery / Q000473:pathology; D051379:Mice; D008808:Mice, Inbred CBA; D009113:Muramidase / Q000737:chemistry / Q000494:pharmacology*; D010641:Phenotype; D012334:RNA, Neoplasm / Q000032:analysis / Q000096:biosynthesis; D013601:T-Lymphocytes / Q000187:drug effects*; D014407:Tumor Cells, Cultured
D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D009113:Muramidase